Today: 2 April 2026
Subscribe
Browse Category

NASDAQ:ABBV 30 January 2026 - 31 January 2026

AbbVie stock (ABBV) firms up into earnings week as markets turn cautious

AbbVie stock (ABBV) firms up into earnings week as markets turn cautious

AbbVie shares rose 1.17% to $223.01 Friday, outperforming a broader market dip after Donald Trump nominated Kevin Warsh to lead the Federal Reserve. Trading volume in AbbVie topped its 50-day average ahead of next week’s earnings report. The stock remains about 9% below its 52-week high. AbbVie will release results and hold its earnings call early Wednesday.
31 January 2026
···
AbbVie stock rises as ABBV heads into Feb. 4 earnings; Botox price talks in focus

AbbVie stock rises as ABBV heads into Feb. 4 earnings; Botox price talks in focus

AbbVie shares rose about 1% Friday, closing near $222.73 ahead of its Feb. 4 earnings report and first 2026 guidance. Investors are watching Botox pricing risks after Medicare listed it for price negotiations, and new aesthetics data from Paris. The stock dropped 2.35% Wednesday, ending a five-day rally. Goldman Sachs kept a neutral rating with a $223 target.
30 January 2026
···

Stock Market Today

  • Citigroup Lowers Loar (NYSE:LOAR) Price Target to $71 Amid Mixed Analyst Ratings
    April 2, 2026, 1:17 PM EDT. Citigroup reduced Loar's price target from $83 to $71, maintaining a "buy" rating despite signaling cautious optimism. The new target implies a 23% upside from current levels. Other analysts show mixed views: Royal Bank of Canada recent price cut to $90 with an "outperform" rating; Zacks and Weiss Ratings hold positions at "hold." Loar's stock fell 1.6% to $57.60 on Thursday, with a market cap of $5.39 billion. The company posted strong Q4 earnings, beating estimates with $0.26 EPS and 19.3% revenue growth. Director Paul S. Levy increased his stake by 0.94%, buying 75,000 shares at $64.90. Overall, Loar holds a "Moderate Buy" consensus and a $89 average price target from analysts.
Go toTop